Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study

Abstract: Background
There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly.

Methods
In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models.

Results
Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93–1.08), p = 0.97). There was no relationship between starting dose of sorafenib 800 mg vs 400 mg/200 mg and OS between those <75 and ≥75 years. The elderly experienced a similar overall incidence of grade 2–4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%, p = 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary between different starting doses of sorafenib.

Conclusions
Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed

Angaben zum Objekt

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch
• Anmerkungen: British journal of cancer. - 124 (2021) , 407–413, ISSN: 1532-1827

Beteiligte, Orts- und Zeitangaben

• Ereignis: Veröffentlichung
• (wo): Freiburg
• (wer): Universität
• (wann): 2023
• Urheber: Hajiev, Saur ; Allara, Elias ; Motedayеn-Aval, Leila ; Arizumi, Tadaaki ; Bettinger, Dominik ; Pirisi, Mario ; Rimassa, Lorenza ; Pressiani, Tiziana ; Personeni, Nicola ; Giordano, Laura ; Kudo, Masatoshi ; Thimme, Robert ; Park, Joong Won ; Taddei, Tamar H. ; Kaplan, David E. ; Ramaswami, Ramya ; Pinato, David James ; Sharma, Rohini

Weitere Informationen

• DOI: 10.1038/s41416-020-01116-9
• URN: urn:nbn:de:bsz:25-freidok-1744395
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Letzte Aktualisierung: 25.03.2025, 13:42 MEZ